A combined approach of structure‐based virtual screening and NMR to interrupt the PD‐1/PD‐L1 axis: Biphenyl‐benzimidazole containing compounds as novel PD‐L1 inhibitors
Archiv der Pharmazie · 2024-03 · 357 (3)
DOI: 10.1002/ardp.202300583 ↗Kurz gefasst
Fachartikel in der Zeitschrift Archiv der Pharmazie, online erschienen am 18.12.2023. Verfasst von Greta Donati und 19 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pharmacy, University of Naples Federico II, Naples, Italy. Hauptthemen laut MEDLINE: Immune Checkpoint Inhibitors, Programmed Cell Death 1 Receptor, Biphenyl Compounds. Die Arbeit wurde bisher 6-mal zitiert (Crossref) und nennt 58 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Fundacja na rzecz Nauki Polskiej, European Regional Development Fund, Ministero dell'Istruzione, dell'Università e della Ricerca.
Abstract (Originalsprache)
Immunotherapy has emerged as a game‐changing approach for cancer treatment. Although monoclonal antibodies (mAbs) targeting the programmed cell death protein 1/programmed cell death protein 1 ligand 1 (PD‐1/PD‐L1) axis have entered the market revolutionizing the treatment landscape of many cancer types, small molecules, although presenting several advantages including the possibility of oral administration and/or reduced costs, struggled to enter in clinical trials, suffering of water insolubility and/or inadequate potency compared with mAbs. Thus, the search for novel scaffolds for both the design of effective small molecules and possible synergistic strategies is an ongoing field of interest. In an attempt to find novel chemotypes, a virtual screening approach was employed, resulting in the identification of new chemical entities with a certain binding capability, the most versatile of which was the benzimidazole‐containing compound 10 . Through rational design, a small library of its derivatives was synthesized and evaluated. The homogeneous time‐resolved fluorescence (HTRF) assay revealed that compound 17 shows the most potent inhibitory activity (IC 50 ) in the submicromolar range and notably, differently from the major part of PD‐L1 inhibitors, exhibits satisfactory water solubility properties. These findings highlight the potential of benzimidazole‐based compounds as novel promising candidates for PD‐L1 inhibition.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Pharmacy, University of Naples Federico II, Naples, Italy.
- Department of Pharmacy, University of Salerno, Fisciano, Italy.
- Istituto di Scienze e Tecnologie Chimiche "Giulio Natta" (SCITEC), Consiglio Nazionale delle Ricerche (CNR), Milan, Italy.
- Department of Chemistry, University of Milan, Milan, Italy.
- Department of Pharmacy, University of Pisa, Pisa, Italy.
- Department of Organic Chemistry, Faculty of Chemistry, Jagiellonian University, Cracow, Poland.
ORCID-Profile: Monica Viviano, Lukasz Skalniak
Förderung
- Fundacja na rzecz Nauki Polskiej
- European Regional Development Fund
- Ministero dell'Istruzione, dell'Università e della Ricerca
- Italian Ministry of Education, University, and Research (MIUR)
- Progetti di Rilevante Interesse Nazionale, PRIN 2017
- PRIN 2022
- POIR
- European Union
Zitieren
APA
Donati, G., Viviano, M., D'Amore, V. M., Cipriano, A., Diakogiannaki, I., Amato, J., Tomassi, S., Brancaccio, D., Russomanno, P., Di Leva, F. S., Arosio, D., Seneci, P., Taliani, S., Magiera-Mularz, K., Musielak, B., Skalniak, L., Holak, T. A., Castellano, S., La Pietra, V., & Marinelli, L. (2024). A combined approach of structure‐based virtual screening and NMR to interrupt the PD‐1/PD‐L1 axis: Biphenyl‐benzimidazole containing compounds as novel PD‐L1 inhibitors. Archiv der Pharmazie, 357(3). https://doi.org/10.1002/ardp.202300583
Vancouver
Donati G, Viviano M, D'Amore VM, Cipriano A, Diakogiannaki I, Amato J, et al. A combined approach of structure‐based virtual screening and NMR to interrupt the PD‐1/PD‐L1 axis: Biphenyl‐benzimidazole containing compounds as novel PD‐L1 inhibitors. Archiv der Pharmazie. 2024;357(3). doi:10.1002/ardp.202300583
BibTeX
@article{Donati2024,
author = {Donati, Greta and Viviano, Monica and D'Amore, Vincenzo Maria and Cipriano, Alessandra and Diakogiannaki, Isidora and Amato, Jussara and Tomassi, Stefano and Brancaccio, Diego and Russomanno, Pasquale and Di Leva, Francesco Saverio and Arosio, Daniela and Seneci, Pierfausto and Taliani, Sabrina and Magiera-Mularz, Katarzyna and Musielak, Bogdan and Skalniak, Lukasz and Holak, Tad A and Castellano, Sabrina and La Pietra, Valeria and Marinelli, Luciana},
title = {A combined approach of structure‐based virtual screening and NMR to interrupt the PD‐1/PD‐L1 axis: Biphenyl‐benzimidazole containing compounds as novel PD‐L1 inhibitors},
journal = {Archiv der Pharmazie},
year = {2024},
volume = {357},
number = {3},
doi = {10.1002/ardp.202300583}
}
EUVIMED